2023 World Conference on Lung Cancer (Posters)-EP13.07. Is Concept of Continuous Immunotherapy Beyond Progression Effective in Small Cell Lung Cancer?

EP13.07. Is Concept of Continuous Immunotherapy Beyond Progression Effective in Small Cell Lung Cancer? - PDF(Slides)

Pdf Summary

In this study, the authors evaluated the effectiveness of continuous immune checkpoint inhibitors (ICIs) beyond progression in small cell lung cancer (SCLC) patients. They retrospectively reviewed the medical courses of SCLC patients treated with chemo-ICIs at their hospital. <br /><br />The results showed that the median progression-free survival (mPFS) was 5.1 months and the median time to treatment failure (mTTF) was 10.3 months. The median overall survival (mOS) was 13.6 months. The overall response rate (ORR) was 67% and the disease control rate (DCR) was 86%. <br /><br />Swimmer plot analysis showed that ICIs were administered beyond progression in 39% of patients, and in 86% of these cases, the time to treatment failure exceeded 12 months. The median cycle of ICIs in these patients was 16. <br /><br />Grade 3 or higher adverse events (AEs) were seen in 58% of patients, with neutropenia being the most common. Grade 3 or 4 immune-related AEs were observed in 8% of cases. There was one treatment-related death. However, no additional safety concerns were identified during ICIs beyond progression. <br /><br />The authors propose a treatment strategy for SCLC, which includes using ICIs beyond progression in specific situations such as systemic/indolent progression, isolated progression in certain sites (e.g., brain, bone), and systemic/sensitive relapse. <br /><br />In conclusion, the study suggests that continuous ICIs beyond progression could be effective in SCLC patients without significant adverse events. This concept may provide a favorable prognosis in selected cases and improve the generally pessimistic clinical courses associated with SCLC.

Asset Subtitle

Ken Yamamoto

Meta Tag

Speaker Ken Yamamoto

Topic SCLC & Neuroendocrine Tumors: Relapse & Salvage Therapy

Keywords

continuous immune checkpoint inhibitors

small cell lung cancer

SCLC patients

chemo-ICIs

progression-free survival

time to treatment failure

overall survival

overall response rate

adverse events

treatment strategy